NervGen Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Adam Rogers
Chief executive officer
CA$181.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1yr |
| CEO ownership | 0.02% |
| Management average tenure | less than a year |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -CA$42m |
| Dec 31 2025 | CA$181k | n/a | -CA$44m |
| Sep 30 2025 | n/a | n/a | -CA$26m |
| Jun 30 2025 | n/a | n/a | -CA$27m |
| Mar 31 2025 | n/a | n/a | -CA$26m |
| Dec 31 2024 | CA$83k | n/a | -CA$24m |
| Sep 30 2024 | n/a | n/a | -CA$24m |
| Jun 30 2024 | n/a | n/a | -CA$23m |
| Mar 31 2024 | n/a | n/a | -CA$20m |
| Dec 31 2023 | CA$157k | n/a | -CA$22m |
| Sep 30 2023 | n/a | n/a | -CA$20m |
| Jun 30 2023 | n/a | n/a | -CA$19m |
| Mar 31 2023 | n/a | n/a | -CA$20m |
| Dec 31 2022 | CA$126k | CA$38k | -CA$21m |
Compensation vs Market: Adam's total compensation ($USD127.50K) is below average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.
CEO
Adam Rogers
Dr. Adam H. Rogers, M.D., is President & CEO of NervGen Pharma Corp. from February 9, 2026 and serves as its Director and has been its Chairman since July 2025 and was its Interim CEO since July 2025 until...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1yr | CA$181.00k | 0.019% $ 40.0k | |
| Co-Founder & Independent Director | no data | CA$181.00k | 1.11% $ 2.4m | |
| Chief Medical Advisor & Director | 1.1yrs | CA$1.19m | 0.15% $ 320.0k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Regulatory Affairs Officer | less than a year | no data | no data | |
| Senior Vice President of Patient Advocacy & Clinical Affairs | less than a year | no data | no data |
Experienced Management: NGEN's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4yrs | CA$181.00k | 0.019% $ 40.0k | |
| Co-Founder & Independent Director | 9.5yrs | CA$181.00k | 1.11% $ 2.4m | |
| Chief Medical Advisor & Director | 5.8yrs | CA$1.19m | 0.15% $ 320.0k | |
| Independent Director | 8.2yrs | CA$181.00k | 0.53% $ 1.1m | |
| Member of Alzheimer's Disease Scientific Advisory Board | 5.5yrs | no data | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 5.5yrs | no data | no data | |
| Independent Director | 2yrs | CA$217.20k | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 5yrs | no data | no data | |
| Lead Independent Director | 4.3yrs | CA$217.20k | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 5.5yrs | no data | no data | |
| Independent Director | 4.8yrs | CA$217.20k | 0.026% $ 55.5k | |
| Member of Alzheimer's Disease Scientific Advisory Board | 5.5yrs | no data | no data |
Experienced Board: NGEN's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 10:46 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NervGen Pharma Corp. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Elemer Piros | Lucid Capital Markets |
| Michael Okunewitch | Maxim Group |